Drug
Tocilizumab (Actemra®)
Status:
To Patients
Condition:
Systemic Sclerosis ILD
Intervention Type:
Subcutaneous (SC) Injection
Funder Type:
Industry
Drug Details
Tocilizumab (Actemra®) is a prescription medicine called an interleukin-6 (IL-6) receptor antagonist. The U.S. Food and Drug Administration (FDA) approved Actemra® (tocilizumab) subcutaneous injection for slowing the rate of decline in pulmonary function in adult patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD), a debilitating condition with limited treatment options. Actemra® is the first biologic therapy approved by the FDA for the treatment of the disease.